Loss of VHL function in ccRCC leads to the constitutive stabilization of these transcription factors, leading to a highly angiogenic environment [41] and HIF2α has recently emerged as a therapeutic target in ccRCC [42]. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.